Drug DiscontinuationIONS announced discontinuation of IONIS-FB-LRx for geographic atrophy (GA) and ION541 for amyotrophic lateral sclerosis (ALS) as both assets demonstrated insufficient efficacy to advance into Phase 3.
Investor UpdatesOverall, the 2Q call offered no meaningful updates, which isn’t surprising given investor focus remains on the mid/late-stage pipeline.
Pipeline ManagementIONS has advanced too many promising drugs (25 clinical programs) that can reduce focus, consume resources, and increase ambiguity around each opportunity.